News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioReliance Corporation Announces Agreement with Barr Pharmaceuticals, Inc. (BRL) to Supply Bulk Virus for the Manufacture of Adenovirus Vaccine for the U.S. Department of Defense


1/6/2009 9:53:18 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--BioReliance Corporation announced today that it has been contracted by Barr Pharmaceuticals, Inc. to supply bulk adenovirus for the manufacture of Duramed Pharmaceuticals, Inc.’s Adenovirus Types 4 and 7 Live Oral Vaccines. Duramed, a subsidiary of Barr Pharmaceuticals, announced on December 11, 2008, that the U.S. Food and Drug Administration has accepted for review Duramed’s Biologics License Application for the vaccines. The vaccines will be used by the U.S. Department of Defense for administration to military personnel.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES